Bulk Drug and API PLI Programs Surpass Investment Targets

The Production Linked Incentive (PLI) scheme for bulk drugs and active pharmaceutical ingredients (APIs) is delivering results that exceed expectations. Launched in 2020 with a financial outlay of ₹6,940 crore, the programme focuses on 41 strategically important products.

By June 2026, cumulative investment reached ₹5,210.74 crore—well above the initially projected ₹4,330 crore. A total of 39 projects have come online, covering the domestic manufacture of 28 active ingredients. Notably, fermentation‑based medicines such as penicillin‑G, clavulanic acid and rifampicin are now produced locally, reducing the country's historic reliance on imports for these essential drugs.

The success of the bulk‑drug and API initiatives has created a ripple effect across the broader pharma ecosystem. Companies are leveraging the incentive framework to upgrade facilities, adopt modern process technologies, and enhance quality standards. The increased domestic capacity not only improves supply security but also positions India as a competitive exporter of high‑quality APIs and bulk intermediates.

Stakeholders, including both large pharmaceutical houses and smaller MSMEs, are benefiting from the clear policy direction and the financial certainty offered by the PLI model. The momentum generated by exceeding investment targets signals strong confidence in India's manufacturing future and sets a benchmark for upcoming incentive programmes in other health‑related sectors.